Skip to main navigation menu Skip to main content Skip to site footer

Technical comment

Vol. 143 No. 3132 (2013)

High-altitude sojourn: a treatment option in allergic asthma

  • Thomas Rothe
DOI
https://doi.org/10.4414/smw.2013.13833
Cite this as:
Swiss Med Wkly. 2013;143:w13833
Published
28.07.2013

References

  1. Rijssenbeek-Nouwens LH, Fieten KB, Bron AO, et al. High-altitude treatment in atopic and non-atopic patients with severe asthma. Eur Respir J. 2012;40:1374–80.
  2. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy. 2008;63:646–59.
  3. Platts-Mills TA, Tovey ER, Mitchel EB, et al. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet. 1982;2:675–8.
  4. Wüthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss study on air pollution and lung diseases in adults. Int Arch Allergy Immunol. 1995;106:149–56.
  5. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368:804–13.
  6. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113:101–8.
  7. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinicial phenotype of chronic severe asthma. Eur Respir J. 2003;22:470–7.
  8. Wenzel SE, Busse WW. Severe asthma: Lessons from the Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119:14–21.
  9. Custovic A, Simpson A, Bardin PG, Le Souëf P. Allergy is an important factor in asthma exacerbation. Pro and Con. Respirology. 2010;15:1021–7.
  10. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111:3–22.
  11. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001–8.
  12. Horvat JC, Starkey MR, Kim RY, et al. Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airway disease. J Immunol. 2010;184:4159–69.
  13. Busse WW, Lemanske jr RF, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010;376-826-34.
  14. Rothe T. Allergy and asthma exacerbation. Respirology. 2011;16:378–9.
  15. Rijssenbeek-Nowens LH, Bel EH. High-altitude treatment: a therapeutic option for patients with severe, refractory asthma. Clin Exp Allergy. 2011;41:775–82.
  16. ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26:812–8.
  17. Chen E, Miller GE. Stress and inflammation in exacerbations of asthma. Brain Behav Immun. 2007;21:993–9.
  18. Sandhu MS, Casale TB. The role of vitamin D in asthma. Ann Allergy Asthma Immunol. 2010;105:191–9.
  19. Sutherland ER, Goleva E, Jackson LP, et al. Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med. 2010;181:699–704.
  20. Mitchell EA, Beasley R, Keil U, et al. The association between tobacco and the risk of asthma, rhinoconjunctivits and eczema in children and adolescents: analyses from phase three of the ISAAC programme. Thorax. 2012;67:941–9.
  21. Renzetti G, Silvestre G, D’Amario C, et al. Less air pollution leads to rapid reduction of airway inflammation and improved airway function in asthmatic children. Pediatrics. 2009;123:1051–8.
  22. Leuenberger Ph, Künzli N, Ackermann-Liebrich U et groupe SAPALDIA. Etude suisse sur la pollution de l’air et les maladies respiratoires chez l’adulte (SAPALDIA). Schweiz Med Wochenschr. 1998;128:150–61.

Most read articles by the same author(s)